Banerjee Subhashis sold $99K of ARTV

Banerjee Subhashis (Chief Medical Officer) sold 8,222 shares of Artiva Biotherapeutics, Inc. (ARTV) at $12.01 on 2026-08-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Banerjee Subhashis
Published Aug 31, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
medium confidence
Mentioned
$ARTV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The transaction is a routine 10b5‑1 sale; market reaction is expected to be minimal.

02

Market read

Small insider sale with limited price impact; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Potential upcoming clinical trial results or partnership announcements that could offset the sale impact.

Relevance 2/10Novelty 2/10Timing: post‑market 2026‑08‑27

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$ARTVNeutralMedium confidence
Context

Chief Medical Officer sold 8,222 shares for $98,735, reducing his stake to 142,047 shares.

Expected impact

minor downward pressure, likely within normal volatility range

Evidence & confidence

Sale size is under $100k and represents a modest percentage of holdings; market typically discounts such routine 10b5‑1 sales.

Market effects

No immediate sector impact; biotech peers unlikely to be affected.

U.S. market only; no regional ripple.

Limited global relevance.

Counterpoint

If the CMO is privy to upcoming positive data, the sale could be a pre‑emptive cash‑out before a catalyst.

Key entities

  • Artiva Biotherapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

  • Banerjee Subhashis

    Chief Medical Officer of Artiva Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.